Kleinostheim News (Bavaria, Germany)

curasan AG has received FDA certification for its new granular bone regeneration material Ceracell® Dental

curasan AG has received European approval for a novel synthetic bone regeneration material

curasan AG has received FDA certification and, therefore, marketing authorization throughout the USA of the synthetic bone replacement material Osbone® Dental which already has been authorized in the EU as Osbone®

curasan AG has received the certification for the synthetic bone regeneration material Cerasorb® M ORTHO from the Canadian authorities, Health Canada

curasan AG has received European approval for its new granular bone regeneration material Ceracell®

curasan AG expects to make a considerable profit instead of the two million euro loss announced for the financial year 2010

Supporting wound healing and tissue regeneration through the extraction of autologous platelet-mediator-concentrate (PMC) – high patient compatibility using autologous blood – No need for centrifuges and external laboratories

curasan AG has concluded a contract with Matricel GmbH, Herzogenrath, which secures exclusive rights for both companies over a jointly developed new product line

curasan AG, listed in the General Standard of the German Stock Exchange, was able to achieve an annual surplus of 0.2 million Euro in the fiscal year 2009

The employees of curasan AG awaited the recently produced batch of Cerasorb® M with particular excitement

In Germany alone, every year about 800,000 tooth implants are placed. In the case of almost every second patient bone augmentation is necessary, because the jawbone atrophy is already too advanced.

curasan AG, listed in the General Standard of the Deutsche Börse AG, is commencing the sale, through a subsidiary, of its synthetic bone regeneration material Cerasorb® M Ortho in the United States

A new study was presented at the 4th Annual Congress of the German Spine Society in Munich – it demonstrated the long-term effect of Curavisc® in the treatment of chronic facet syndrome

curasan AG has received CE certification and, therefore, marketing authorization throughout Europe of the synthetic bone replacement material Osbone®

curasan AG, which is listed on the General Standard of the German Stock Exchange, has signed a research and development agreement with the Ben-Gurion University of the Negev (BGU), Israel

curasan AG has been received CE certification and, therefore, marketing authorization for the ATR® (Advanced Tissue Regeneration) product

curasan AG is to invest in its future growth by implementing a technological investment programme amounting to approximately 1 million euros, despite the current crisis in the financial markets

Outstanding suitability of Cerasorb® M for tissue engineering – Studies confirm positive results regarding the colonisation of Cerasorb® M with various types of cells

curasan AG presented innovative medical products from the Cerasorb® umbrella brand at the 57th annual congress of the Association of South-German Orthopaedic Surgeons (Vereinigung Süddeutscher Orthopäden e. V.)